Press Releases

2010-02-26	Change in numbers of shares in BioPhausia AB

2010-02-16	Claes Thulin leaving BioPhausia

2008-09-30	Change in numbers of shares in BioPhausia AB

2008-09-11	Final results of BioPhausia's rights issue

2008-09-05	BioPhausia's board of directors intend to propose a reverse split 1:10 of the company's shares

2008-09-03	BioPhausia's rights issue fully subscribed

2008-08-06	Financial goals for BioPhausia

2008-08-04	BioPhausia's extraordinary shareholders' meeting approved the rights issue 2:1 at an issue price of SEK 1.35 per share

2008-07-31	Exchange ratio and subscription price set for the rights issue in BioPhausia – 2:1 and SEK 1.35 Respectively

2008-07-01	Notice of Extraordinary general meeting in BioPhausia AB (publ), August 4, 2008

2008-07-01	Rights issue in BioPhausia AB to finance the acquisition of the pharmaceutical products portfolio acquired from AstraZeneca AB

2008-06-30	BioPhausia completes the acquisition of a pharmaceutical product portfolio from AstraZeneca AB

2008-05-26	BioPhausia acquires pharmaceutical portfolio from AstraZeneca

2008-04-08	Notice of the 2008 annual general meeting

2007-05-11	Press release from the annual general meeting of BioPhausia AB (Publ), 10 May 2007

2007-04-03	Notice of the 2007 Annual General Meeting

2006-12-05	BioPhausia raises SEK 46 million in new share issue to partly refinance the acquisition of a portfolio of 17 products from AstraZeneca

2006-11-30	BioPhausia completes acquisition of portfolio of pharmaceuticals from AstraZeneca AB

2006-11-15	BioPhausia acquires pharmaceutical products portfolio from AstraZeneca AB

2008-09-30	Change in numbers of shares in BioPhausia AB

2008-09-11	Final results of BioPhausia's rights issue

2008-09-05	BioPhausia's board of directors intend to propose a reverse split 1:10 of the company's shares

2008-09-03	BioPhausia's rights issue fully subscribed

2008-08-06	Financial goals for BioPhausia

2008-08-04	BioPhausia's extraordinary shareholders' meeting approved the rights issue 2:1 at an issue price of SEK 1.35 per share

2008-07-31	Exchange ratio and subscription price set for the rights issue in BioPhausia – 2:1 and SEK 1.35 Respectively

2008-07-01	Notice of Extraordinary general meeting in BioPhausia AB (publ), August 4, 2008

2008-07-01	Rights issue in BioPhausia AB to finance the acquisition of the pharmaceutical products portfolio acquired from AstraZeneca AB

2008-06-30	BioPhausia completes the acquisition of a pharmaceutical product portfolio from AstraZeneca AB

2008-05-26	BioPhausia acquires pharmaceutical portfolio from AstraZeneca

2008-04-08	Notice of the 2008 annual general meeting

2007-05-11	Press release from the annual general meeting of BioPhausia AB (Publ), 10 May 2007

2007-04-03	Notice of the 2007 Annual General Meeting

2006-12-05	BioPhausia raises SEK 46 million in new share issue to partly refinance the acquisition of a portfolio of 17 products from AstraZeneca

2006-11-30	BioPhausia completes acquisition of portfolio of pharmaceuticals from AstraZeneca AB

2006-11-15	BioPhausia acquires pharmaceutical products portfolio from AstraZeneca AB